Subclinical cardiac disease in ankylosing spondylitis. Issue 10 (29th July 2018)

• Record Type: Journal Article
• Authors: Ozen, Selin; Ozen, Anil; Unal, Ertekin U.; Tufekcioglu, Omac; Ataman, Sebnem; Yalcin, Ayse P.
• Is Part Of: Echocardiography. Volume 35:Issue 10(2018)
• Page Start: 1579
• Page End: 1586
• Publication Date: 2018-07-29
• Subjects: ankylosing spondylitis -- aortic stiffness -- echocardiography -- systolic function; Echocardiography -- Periodicals; Echocardiography -- Periodicals; 616.1207543
• DOI: 10.1111/echo.14103
• Languages: English
• ISSNs: 0742-2822

Abstract

Abstract : Objectives: To investigate aortic stiffness and subclinical left ventricular systolic dysfunction in ankylosing spondylitis (AS) patients. Methods: A cross‐sectional study of 55 AS patients being treated with antitumor necrosis factor alpha (anti–TNF‐α) biological agents, conventional synthetic disease‐modifying antirheumatic drugs (csDMARDS), and non steroidal anti‐inflammatory drugs (NSAIDs) and 20 controls matched for conventional cardiovascular risk factors. Aortic stiffness, ejection fraction, and left ventricular global longitudinal strain (LVGLS) were evaluated using transthoracic echocardiography and 2D Doppler echocardiography. Results: Aortic stiffness was higher in AS patients when compared to controls ( P = 0.009). Stiffness increased in those being treated with csDMARDs when compared to the control group and those on anti–TNF‐α biologics ( P ˂0.001). AS patients' LVGLS values were worse than those of the control group ( P < 0.001) and also worse in patients on csDMARDs and anti–TNF‐α biologics when compared to those being treated with NSAIDs ( P < 0.001). Conclusions: Subclinical cardiac dysfunction occurs in AS patients despite well controlled musculoskeletal disease. Aortic stiffness and LVGLS increases in AS patients. Anti‐TNF biological agents may somewhat protect arterial compliance. We believe that all AS patients should be investigated for cardiac dysfunction and followed up accordingly.